Rigel Pharmaceuticals Secures Global License for VEPPANU, First FDA-Approved Oral PROTAC, from Arvinas and Pfizer

The first FDA-approved oral PROTAC has changed hands commercially, and the manufacturing and quality infrastructure required to support it now falls to Rigel Pharmaceuticals. On May 12, 2026, Rigel announced an exclusive global licensing agreement with Arvinas and Pfizer to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant) for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, a deal structured around an upfront $70.0 million payment, a further $15.0 million tied to transition milestones, and up to $320.0 million in future regulatory and commercial milestone payments.

For plant heads and QA directors, the significance of this transaction extends well beyond the commercial terms. PROTACs are heterobifunctional protein degraders, structurally more complex than conventional small molecules, and VEPPANU's approval establishes the first real-world CMC precedent for this drug class under 21 CFR Part 211. The synthesis pathway involves two distinct binding ligands linked by a chemical tether, each requiring independent characterization, with degrader activity dependent on ternary complex formation. Process validation strategies, impurity profiling, and analytical method development for this class carry a level of complexity that existing small-molecule frameworks only partially address.

The clinical rationale is grounded in the pivotal VERITAC-2 Phase 3 trial (NCT05654623), results of which were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine. Vepdegestrant demonstrated a median progression-free survival of 5.0 months versus 2.1 months for fulvestrant in 2L+ ER+/HER2- metastatic breast cancer patients with an ESR1 mutation, a 2.4-fold improvement. The FDA accepted the NDA on August 8, 2025, assigned a PDUFA date of June 5, 2026, and granted approval on May 1, 2026.

Rigel's existing commercial infrastructure, built across three prior product launches, will absorb VEPPANU as its fourth commercial asset. The transition activities tied to the $15.0 million contingent payment will require close coordination between Rigel's quality and regulatory teams and the outgoing CMC holders at Arvinas and Pfizer. Technology transfer protocols, batch record alignment, and supplier qualification under ICH Q10 principles will be central to maintaining sterility assurance and product quality through the handover period.

As additional PROTAC candidates advance through late-stage development across the industry, the quality control frameworks and regulatory precedents established during VEPPANU's commercial scale-up will serve as the operational baseline against which future submissions are benchmarked.

Source: Rigel Pharmaceuticals, Inc. press release via PRNewswire, May 12, 2026. Conference call held at 8:00 a.m. Eastern Time on the same date.